Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Thomas P. Miller, Stephen E. Jones, David S. Alberts, Cindy Mackel

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalInvestigational New Drugs
Volume2
Issue number1
DOIs
StatePublished - Mar 1 1984

Keywords

  • bisantrene
  • non-Hodgkin's lymphomas

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas'. Together they form a unique fingerprint.

Cite this